If discomfort persists, discontinue use and seek medical advice
dosing with 100 nmol kg 1 MK-801, 100 nmol kg 1 GLP-1, 100 nmol kg 1 GLP-1MK-801 or vehicle
Higher-risk situations may include: Older age Existing sarcopenia or frailty Recent falls Difficulty rising from a chair Low baseline physical activity Very low protein or calorie intake Rapid or excessive appetite suppression Chronic kidney, liver, pulmonary, or cardiovascular disease Cancer or another catabolic illness Recent hospitalization Significant gastrointestinal adverse effects Very rapid weight loss Inability to participate in resistance exercise These factors do not automatically make GLP-1 therapy inappropriate
A connected, reusable add-on provides advanced patient guidance and detailed injection logging, but adds user steps, which may be best suited to certain therapies where patient behavior is critical and closely monitored
Discontinuation of treatment (37%) was the most common reason for censoring (Supplementary Table 20)